<DOC>
	<DOCNO>NCT01618864</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Luxe™ device use wrinkle rosacea treatment . Up 60 subject treat periorbital cheek area daily 4 week twice week additional 4 week . Evaluations improvement conduct clinic enrollment treatment 1 , 2 , 4 , 8 week initiation .</brief_summary>
	<brief_title>Safety Efficacy Luxe Device Treat Facial Wrinkles Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>1 . Healthy male female age 21 60 . 2 . Nonsmoker . 3 . Have prior experience Luxe™ device . 4 . Having wrinkle , rhytides fine line periorbital region classify wrinkle type 13 Crow 's Feet Grading Scale and/or rosacea cheek region . 5 . Able willing comply visit , treatment evaluation schedule requirement . 6 . Agree make change exist skincare regime , use study product , study period . 7 . Able understand provide write Informed Consent . 8 . Women childbearing age pas negative pregnancy test , require use reliable method birth control least 3 month prior throughout study enrollment . 1 . Fail meet inclusion criterion . 2 . Subject unable unwilling provide proper informed consent participation . 3 . Subject able understand requirement study . 4 . Pregnant nursing woman intend become pregnant course study . 5 . Reported one follow medical condition could result potential harm : Obvious cognitive deficit . Neuromotor control difficulty either hand . Sensitivity light . History light activate medical problem light triggered seizure disorder migraine headache . Taking drug may cause light sensitivity . 6 . Having active electrical implant anywhere body , pacemaker internal defibrillator . 7 . Having permanent implant treat area , metal plate screw 8 . Unable unlikely refrain tanning , include use tan booth , course study . 9 . Prior current skin therapy may interfere evaluation study device : Renova , AHAs , Vitamin C , Kinerase , Tretinoin , Topical Retinoids , Topical Steroids , Antibiotics ( topical oral ) within 14 day baseline visit . Oral Retinoids within 6 month baseline visit . 10 . Use oral Isotretinoin ( Accutane® ) within 6 month initial treatment course study . 11 . Subject currently treat dermatologic condition may interfere safe evaluation study device ( Eczema , Psoriasis , Severe sun damage , Dermatitis ) . 12 . Patient systemic corticosteroid therapy 6 month prior throughout course study . 13 . Subject history hypersensitivity allergy ( LED ) light . 14 . Subject history hypersensitivity allergy formulation device component . 15 . Having receive facial dermabrasion chemical peel treatment within 3 month treatment study . 16 . Prior skin treatment laser treat area within 3 month initial treatment course study . 17 . Prior use Botox , collagen , fat injection /or method skin augmentation ( enhancement inject implanted material ) treat area within 2 month initial treatment course study . Treatment may perform , , permanent dermal implant . 18 . Prior ablative resurfacing procedure , brow lift , blepharoplasty face lift treat area laser device within 12 month initial treatment course study . 19 . Any surgery treat area within 12 month initial treatment course study . 20 . History keloid formation poor wound heal previously injure skin area . 21 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) . 22 . Open laceration abrasion sort area treat . 23 . Active Herpes Simplex I time treatment . 24 . Multiple dysplastic nevi area treat . 25 . Having bleed disorder take anticoagulation medication , include heavy use aspirin , manner allow minimum 10 day washout period prior treatment ( per subject 's physician discretion ) . 26 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) use immunosuppressive medication . 27 . Having form active cancer ( especially skin cancer : BCC , SCC , Melanoma ) time enrollment course study . 28 . Significant concurrent illness , uncontrolled diabetes i.e . disease state opinion investigator would interfere treatment , heal process . 29 . Subjects initiated treatment hormone include estrogen , progesterone , oral contraceptive 12 week less , immediately precede study entry , intend discontinue hormonal therapy study . 30 . Participation study another device drug within 1 month prior study enrollment study , per Investigator 's careful discretion , long contradictory criterion . 31 . Subjects history past present drug/ alcohol abuse . 32 . Mentally incompetent , prisoner evidence active substance . 33 . Any condition , Investigator 's opinion , would make unsafe ( subject study personnel ) treat subject part research .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>